Cadence Pharmaceuticals Inc. (CADX)

[surf1944]

7:03AM Cadence Pharma announces settlement of OFIRMEV injection patent litigation with Perrigo Company (PRGO) (CADX) 3.77 : Co announced that it has entered into settlement and license agreements with Perrigo Company (PRGO), and its subsidiary, Paddock Laboratories, LLC, to resolve pending patent litigation involving OFIRMEV injection. The settlement agreement includes a stipulation by the parties requesting dismissal with prejudice of the lawsuit filed by Cadence in the U.S. District Court for the District of Delaware relating to the Abbreviated New Drug Application, or ANDA, filed by Paddock with the U.S. Food and Drug Administration for a generic version of OFIRMEV. The license agreement also provides that, if the parties enter into an agreement for Perrigo to market an authorized generic version of OFIRMEV, during the license period, Perrigo would purchase the product exclusively from Cadence.